tiprankstipranks
Trending News
More News >
Bio-Techne (TECH)
:TECH
US Market
Advertisement

Bio-Techne (TECH) Stock Forecast & Price Target

Compare
507 Followers
See the Price Targets and Ratings of:

TECH Analyst Ratings

Strong Buy
11Ratings
Strong Buy
9 Buy
2 Hold
0 Sell
Based on 11 analysts giving stock ratings to
Bio-Techne
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

TECH Stock 12 Month Forecast

Average Price Target

$67.70
▲(34.67%Upside)
Based on 11 Wall Street analysts offering 12 month price targets for Bio-Techne in the last 3 months. The average price target is $67.70 with a high forecast of $80.00 and a low forecast of $59.00. The average price target represents a 34.67% change from the last price of $50.27.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"47":"$47","82":"$82","55.75":"$55.8","64.5":"$64.5","73.25":"$73.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":80,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$80.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":67.7,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$67.70</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":59,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$59.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[47,55.75,64.5,73.25,82],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2024","6":"Jan<br/>2025","9":"Apr<br/>2025","12":"Jul<br/>2025","25":"Jul<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,52.08,54.22769230769231,56.37538461538461,58.52307692307692,60.67076923076923,62.818461538461534,64.96615384615384,67.11384615384615,69.26153846153846,71.40923076923076,73.55692307692308,75.70461538461538,77.85230769230769,{"y":80,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,52.08,53.28153846153846,54.48307692307692,55.684615384615384,56.886153846153846,58.08769230769231,59.28923076923077,60.49076923076923,61.69230769230769,62.893846153846155,64.09538461538462,65.29692307692308,66.49846153846154,{"y":67.7,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,52.08,52.61230769230769,53.144615384615385,53.676923076923075,54.20923076923077,54.74153846153846,55.27384615384615,55.80615384615385,56.33846153846154,56.87076923076923,57.403076923076924,57.93538461538461,58.46769230769231,{"y":59,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":76.81,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":81.94,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":73.7,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":77.87,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":75.02,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":75.8,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":71.83,"date":1735689600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":73.34,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":61.65,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":57.26,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":49.55,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":48.61,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":52.08,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$80.00Average Price Target$67.70Lowest Price Target$59.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TipRanks Analyst forecast on TECH
TipRanks AITipRanks
Not Ranked
TipRanks
$59
Buy
17.37%
Upside
Reiterated
07/19/25
Bio-Techne's strong profitability, strategic share repurchase program, and solid earnings call drive a positive outlook. However, high valuation and macroeconomic uncertainties like NIH funding and tariff challenges pose significant risks.
Stephens Analyst forecast on TECH
Steven EtochStephens
Stephens
$65
Buy
29.30%
Upside
Initiated
07/21/25
Bio-Techne resumed with an Overweight at StephensBio-Techne resumed with an Overweight at Stephens
TD Cowen
$65
Buy
29.30%
Upside
Initiated
07/16/25
Analysts Offer Insights on Healthcare Companies: Bio-Techne (NASDAQ: TECH) and Surgery Partners (NASDAQ: SGRY)
Scotiabank Analyst forecast on TECH
Sung Ji NamScotiabank
Scotiabank
$90$75
Buy
49.19%
Upside
Reiterated
07/11/25
Scotiabank Sticks to Its Buy Rating for Bio-Techne (TECH)
RBC Capital Analyst forecast on TECH
Conor McNamaraRBC Capital
RBC Capital
$63
Hold
25.32%
Upside
Reiterated
06/30/25
RBC Capital Sticks to Their Hold Rating for Bio-Techne (TECH)
Stifel Nicolaus Analyst forecast on TECH
Daniel AriasStifel Nicolaus
Stifel Nicolaus
$60
Hold
19.36%
Upside
Reiterated
06/27/25
Stifel Nicolaus Remains a Hold on Bio-Techne (TECH)
Benchmark Co. Analyst forecast on TECH
Robert WassermanBenchmark Co.
Benchmark Co.
$75
Buy
49.19%
Upside
Reiterated
06/05/25
Benchmark Co. Keeps Their Buy Rating on Bio-Techne (TECH)
Wells Fargo
$59
Buy
17.37%
Upside
Initiated
05/30/25
Bio-Techne: Strong Market Position and Growth Potential Justify Buy Rating
Argus Research Analyst forecast on TECH
David ToungArgus Research
Argus Research
$90$65
Buy
29.30%
Upside
Reiterated
05/30/25
Argus Research Reaffirms Their Buy Rating on Bio-Techne (TECH)
UBS
$95$70
Buy
39.25%
Upside
Reiterated
05/09/25
Bio-Techne price target lowered to $70 from $95 at UBSBio-Techne price target lowered to $70 from $95 at UBS
William Blair Analyst forecast on TECH
Matt LarewWilliam Blair
William Blair
Buy
Reiterated
05/07/25
Bio-Techne's Resilience and Strong Financial Performance Justify Buy Rating Amid Market Challenges
Leerink Partners Analyst forecast on TECH
Puneet SoudaLeerink Partners
Leerink Partners
$80
Buy
59.14%
Upside
Reiterated
05/07/25
Analysts Are Bullish on Top Healthcare Stocks: Bio-Techne (TECH), Mirum Pharmaceuticals (MIRM)
Robert W. Baird
$68$51
Buy
1.45%
Upside
Reiterated
04/21/25
Bio-Techne price target lowered to $51 from $68 at BairdBio-Techne price target lowered to $51 from $68 at Baird
KeyBanc
$90
Hold
79.03%
Upside
Downgraded
04/08/25
Bio-Techne downgraded to Sector Weight from Overweight at KeyBancBio-Techne downgraded to Sector Weight from Overweight at KeyBanc
Evercore ISI
$75
Buy
49.19%
Upside
Initiated
03/18/25
Bio-Techne: A Premium Growth Asset with Strong Market Position and Promising Future
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TipRanks Analyst forecast on TECH
TipRanks AITipRanks
Not Ranked
TipRanks
$59
Buy
17.37%
Upside
Reiterated
07/19/25
Bio-Techne's strong profitability, strategic share repurchase program, and solid earnings call drive a positive outlook. However, high valuation and macroeconomic uncertainties like NIH funding and tariff challenges pose significant risks.
Stephens Analyst forecast on TECH
Steven EtochStephens
Stephens
$65
Buy
29.30%
Upside
Initiated
07/21/25
Bio-Techne resumed with an Overweight at StephensBio-Techne resumed with an Overweight at Stephens
TD Cowen
$65
Buy
29.30%
Upside
Initiated
07/16/25
Analysts Offer Insights on Healthcare Companies: Bio-Techne (NASDAQ: TECH) and Surgery Partners (NASDAQ: SGRY)
Scotiabank Analyst forecast on TECH
Sung Ji NamScotiabank
Scotiabank
$90$75
Buy
49.19%
Upside
Reiterated
07/11/25
Scotiabank Sticks to Its Buy Rating for Bio-Techne (TECH)
RBC Capital Analyst forecast on TECH
Conor McNamaraRBC Capital
RBC Capital
$63
Hold
25.32%
Upside
Reiterated
06/30/25
RBC Capital Sticks to Their Hold Rating for Bio-Techne (TECH)
Stifel Nicolaus Analyst forecast on TECH
Daniel AriasStifel Nicolaus
Stifel Nicolaus
$60
Hold
19.36%
Upside
Reiterated
06/27/25
Stifel Nicolaus Remains a Hold on Bio-Techne (TECH)
Benchmark Co. Analyst forecast on TECH
Robert WassermanBenchmark Co.
Benchmark Co.
$75
Buy
49.19%
Upside
Reiterated
06/05/25
Benchmark Co. Keeps Their Buy Rating on Bio-Techne (TECH)
Wells Fargo
$59
Buy
17.37%
Upside
Initiated
05/30/25
Bio-Techne: Strong Market Position and Growth Potential Justify Buy Rating
Argus Research Analyst forecast on TECH
David ToungArgus Research
Argus Research
$90$65
Buy
29.30%
Upside
Reiterated
05/30/25
Argus Research Reaffirms Their Buy Rating on Bio-Techne (TECH)
UBS
$95$70
Buy
39.25%
Upside
Reiterated
05/09/25
Bio-Techne price target lowered to $70 from $95 at UBSBio-Techne price target lowered to $70 from $95 at UBS
William Blair Analyst forecast on TECH
Matt LarewWilliam Blair
William Blair
Buy
Reiterated
05/07/25
Bio-Techne's Resilience and Strong Financial Performance Justify Buy Rating Amid Market Challenges
Leerink Partners Analyst forecast on TECH
Puneet SoudaLeerink Partners
Leerink Partners
$80
Buy
59.14%
Upside
Reiterated
05/07/25
Analysts Are Bullish on Top Healthcare Stocks: Bio-Techne (TECH), Mirum Pharmaceuticals (MIRM)
Robert W. Baird
$68$51
Buy
1.45%
Upside
Reiterated
04/21/25
Bio-Techne price target lowered to $51 from $68 at BairdBio-Techne price target lowered to $51 from $68 at Baird
KeyBanc
$90
Hold
79.03%
Upside
Downgraded
04/08/25
Bio-Techne downgraded to Sector Weight from Overweight at KeyBancBio-Techne downgraded to Sector Weight from Overweight at KeyBanc
Evercore ISI
$75
Buy
49.19%
Upside
Initiated
03/18/25
Bio-Techne: A Premium Growth Asset with Strong Market Position and Promising Future
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Bio-Techne

1 Month
xxx
Success Rate
24/35 ratings generated profit
69%
Average Return
+1.72%
reiterated a xxx
rating 3 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 68.57% of your transactions generating a profit, with an average return of +1.72% per trade.
3 Months
xxx
Success Rate
10/15 ratings generated profit
67%
Average Return
+1.05%
reiterated a xxx
rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 66.67% of your transactions generating a profit, with an average return of +1.05% per trade.
1 Year
Success Rate
19/35 ratings generated profit
54%
Average Return
+9.77%
reiterated a buy rating 3 months ago
Copying Catherine Ramsey Schulte's trades and holding each position for 1 Year would result in 54.29% of your transactions generating a profit, with an average return of +9.77% per trade.
2 Years
xxx
Success Rate
17/35 ratings generated profit
49%
Average Return
+16.75%
reiterated a xxx
rating 3 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 48.57% of your transactions generating a profit, with an average return of +16.75% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

TECH Analyst Recommendation Trends

Rating
Mar 25
Apr 25
May 25
Jun 25
Jul 25
Strong Buy
0
1
3
4
3
Buy
7
8
7
8
14
Hold
5
7
6
9
6
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
12
16
16
21
23
In the current month, TECH has received 17 Buy Ratings, 6 Hold Ratings, and 0 Sell Ratings. TECH average Analyst price target in the past 3 months is 67.70.
Each month's total comprises the sum of three months' worth of ratings.

TECH Financial Forecast

TECH Earnings Forecast

Next quarter’s earnings estimate for TECH is $0.50 with a range of $0.47 to $0.52. The previous quarter’s EPS was $0.56. TECH beat its EPS estimate 75.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.14% of the time in the same period. In the last calendar year TECH has Outperformed its overall industry.
Next quarter’s earnings estimate for TECH is $0.50 with a range of $0.47 to $0.52. The previous quarter’s EPS was $0.56. TECH beat its EPS estimate 75.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.14% of the time in the same period. In the last calendar year TECH has Outperformed its overall industry.

TECH Sales Forecast

Next quarter’s sales forecast for TECH is $314.61M with a range of $311.40M to $322.70M. The previous quarter’s sales results were $316.18M. TECH beat its sales estimates 50.00% of the time in past 12 months, while its overall industry beat sales estimates 47.52% of the time in the same period. In the last calendar year TECH has Outperformed its overall industry.
Next quarter’s sales forecast for TECH is $314.61M with a range of $311.40M to $322.70M. The previous quarter’s sales results were $316.18M. TECH beat its sales estimates 50.00% of the time in past 12 months, while its overall industry beat sales estimates 47.52% of the time in the same period. In the last calendar year TECH has Outperformed its overall industry.

TECH Stock Forecast FAQ

What is TECH’s average 12-month price target, according to analysts?
Based on analyst ratings, Bio-Techne’s 12-month average price target is 67.70.
    What is TECH’s upside potential, based on the analysts’ average price target?
    Bio-Techne has 34.67% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is TECH a Buy, Sell or Hold?
          Bio-Techne has a consensus rating of Strong Buy which is based on 9 buy ratings, 2 hold ratings and 0 sell ratings.
            What is Bio-Techne’s price target?
            The average price target for Bio-Techne is 67.70. This is based on 11 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $80.00 ,the lowest forecast is $59.00. The average price target represents 34.67% Increase from the current price of $50.27.
              What do analysts say about Bio-Techne?
              Bio-Techne’s analyst rating consensus is a Strong Buy. This is based on the ratings of 11 Wall Streets Analysts.
                How can I buy shares of TECH?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis